Publications by Karianne Giller Fleten

22 publications found

  1. Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2024)
    A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
    Cancer Res (in press)
    DOI 10.1158/0008-5472.CAN-24-0323, PubMed 39700396
  2. Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
    Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
    Cancer Res, 83 (19), 3184-3191
    DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032
  3. Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
    Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
    bioRxiv
    DOI 10.1101/2023.02.01.526672, PubMed 36993681
  4. Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
    Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
    Nanomedicine, 48, 102656
    DOI 10.1016/j.nano.2023.102656, PubMed 36646195
  5. Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
    Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
    Mar Drugs, 20 (12)
    DOI 10.3390/md20120744, PubMed 36547891
  6. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
    Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
    J Control Release, 349, 1
    DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
  7. Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
    AXL inhibition improves BRAF-targeted treatment in melanoma
    Sci Rep, 12 (1), 5076
    DOI 10.1038/s41598-022-09078-z, PubMed 35332208
  8. Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
    Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
    J Immunother Cancer, 9 (10)
    DOI 10.1136/jitc-2021-003109, PubMed 34711663
  9. Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
    Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
    Cancers (Basel), 13 (11)
    DOI 10.3390/cancers13112819, PubMed 34198773
  10. Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
    Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
    J Gastrointest Oncol, 12 (Suppl 1), S191-S203
    DOI 10.21037/jgo-20-136, PubMed 33968437
  11. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
    Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
    Sci Rep, 11 (1), 6731
    DOI 10.1038/s41598-021-86239-6, PubMed 33762676
  12. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
    Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
    Transl Oncol, 13 (8), 100793
    DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
  13. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
    Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
    J Control Release, 293, 183-192
    DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
  14. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
    MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
    Oncotarget, 8 (37), 61800-61809
    DOI 10.18632/oncotarget.18694, PubMed 28977905
  15. Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
    hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
    Cell Death Discov, 2, 16081
    DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
  16. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
    Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
    Clin Exp Metastasis, 34 (1), 51-62
    DOI 10.1007/s10585-016-9829-3, PubMed 27812769
  17. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
    Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Radiother Oncol, 119 (3), 505-11
    DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754
  18. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
    Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Oncotarget, 7 (15), 19997-20015
    DOI 10.18632/oncotarget.7671, PubMed 26918352
  19. Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J (2015)
    Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
    PLoS One, 10 (6), e0128816
    DOI 10.1371/journal.pone.0128816, PubMed 26066655
  20. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
    Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
    Int J Cancer, 133 (6), 1497-506
    DOI 10.1002/ijc.28158, PubMed 23494569
  21. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
    Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
    Radiat Oncol, 7, 165
    DOI 10.1186/1748-717X-7-165, PubMed 23017053
  22. Størvold GL, Fleten KG, Olsen CG, Follestad T, Krokan HE, Schønberg SA (2009)
    Docosahexaenoic acid activates some SREBP-2 targets independent of cholesterol and ER stress in SW620 colon cancer cells
    Lipids, 44 (8), 673-83
    DOI 10.1007/s11745-009-3324-4, PubMed 19582494

 

 
Scroll to top